This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The authors stated that a societal perspective was adopted, but the cost categories reflected a third-party payer viewpoint. The sources were typical of those used in US studies and the costs were generally presented as category totals, as often occurs when Medicare data are used. The resource use and unit costs were not presented separately. Some of the costs were varied in the sensitivity analysis. Other details, such as the price year and discount rate, were given.
Analysis and results:
The costs and benefits were extensively presented for all strategies and both average and incremental ratios were calculated. The uncertainty was addressed in one-way sensitivity analyses, which focused on the key model parameters, due to the large number of strategies compared. The authors stated that conservative assumptions were generally made and some potential benefits from genetic tests were omitted. Conventional discounting was applied to both the costs and benefits. The results appear to be typical of the US setting and it is not clear whether they are transferable to other settings.
Concluding remarks:
The study was well presented and the methods were valid and accurate. The authors' conclusions are robust.
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